2026-10-13T01:54:47Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33903530 2026-09-17T17:25:39Z category_7 category_12 category_16 category_19 category_21 category_46 category_64 category_106 category_132 portal_5 item_type_3 month_year_09_2026

<p>The clinical characteristics of reports of eribulin in the FAERS database (Q1 2011 to Q2 2024).</p> Yao Zhou (1521676) Jie Gong (339362) Lele Shen (16390038) Jie Ling (381425) Shiting Wu (1424434) Anqi Ge (4670995) Lin Qi (128224) Lifang Liu (2630389) Medicine Cell Biology Physiology Pharmacology Biotechnology Immunology Cancer Science Policy Infectious Diseases world study based serious unexpected aes q2 2024 ). preferred term level met significance across primary suspect drug related ae reports guide clinical use lymphatic adverse events xlink "> eribulin clinical use adverse events drug inserts adverse event respiratory failure q1 2011 predominantly female pleural effusion included patients four algorithms febrile neutropenia enhanced monitoring disproportionality analyses consistently referenced cardiac failure 61 %). 59 years &# 8220 <p>The clinical characteristics of reports of eribulin in the FAERS database (Q1 2011 to Q2 2024).</p> 2026-09-17T17:25:26Z Dataset Dataset 10.1371/journal.pone.0356800.t001 https://figshare.com/articles/dataset/_p_The_clinical_characteristics_of_reports_of_eribulin_in_the_FAERS_database_Q1_2011_to_Q2_2024_p_/33903530 CC BY 4.0